Systematic Review on the Incidence of Bisphosphonate Related Osteonecrosis of the Jaw in Children Diagnosed with Osteogenesis Imperfecta

Overview

Journal J Oral Maxillofac Res

Date 2014 Jan 31

PMID 24478911

Citations 20

Authors

Anusha Adeline Hennedige

Jap Jayasinghe

Janette Khajeh

Tatiana V Macfarlane

Affiliations

Soon will be listed here.

Abstract

Objectives: To conduct a systematic review of epidemiological literature to determine the incidence of bisphosphonate related osteonecrosis of the jaw occurring either spontaneously or after dental surgery, in children and adolescents diagnosed with osteogenesis imperfecta.

Material And Methods: MEDLINE, HMIC and EMBASE were used to search for English-language articles published from 1946 - 2013. Inclusion criteria consisted of population based studies of children and adolescents (24 years and younger) diagnosed with osteogenesis imperfecta, only studies which included a dental examination, and patients treated with intravenous bisphosphonates were included. Articles were excluded if patients had any other co-morbidity which could affect osteonecrosis of the jaw, and those which treated patients with oral bisphosphonates only.

Results: Five studies consisting of four retrospective cohort studies and one case series were identified. Study populations ranged from 15 to 278 patients and number of subjects with osteogenesis imperfecta ranged from 15 to 221. Mean duration of intravenous bisphosphonate use ranged from 4.5 to 6.8 years. All patients were clinically examined and no patients were found to have osteonecrosis of the jaw.

Conclusions: There is no evidence to support hypothesis of causal relationship between bisphosphonates and osteonecrosis of the jaw in children and adolescents with osteogenesis imperfecta. More prospective studies on bisphosphonate use in osteogenesis imperfecta needs to be carried out.

Citing Articles

Efficacy and Safety of Bisphosphonates in Chronic Non-bacterial Osteomyelitis of the Mandible: A Systematic Review.

Howlader D, Daga D, Das A, Baisya R, Babaria B Calcif Tissue Int. 2025; 116(1):47.

PMID: 40055217 DOI: 10.1007/s00223-025-01354-0.

Bone health in childhood cancer survivors, is there really a problem? Pitfalls of assessment, calculating risk, and suggested surveillance and management for osteonecrosis and low and very low bone mineral density.

de Winter D, Neggers S, van den Heuvel-Eibrink M, van Atteveld J Endocr Connect. 2024; 13(12).

PMID: 39437150 PMC: 11623254. DOI: 10.1530/EC-24-0487.

A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence.

Ward L Front Endocrinol (Lausanne). 2024; 14:1266986.

PMID: 38374961 PMC: 10875302. DOI: 10.3389/fendo.2023.1266986.

The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review.

Rapoport M, Bober M, Raggio C, Wekre L, Rauch F, Westerheim I Orphanet J Rare Dis. 2023; 18(1):34.

PMID: 36814274 PMC: 9945474. DOI: 10.1186/s13023-023-02627-3.

Hereditary Metabolic Bone Diseases: A Review of Pathogenesis, Diagnosis and Management.

Charoenngam N, Nasr A, Shirvani A, Holick M Genes (Basel). 2022; 13(10).

PMID: 36292765 PMC: 9601711. DOI: 10.3390/genes13101880.

References

Bagan J, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis J . Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2005; 42(3):327-9. DOI: 10.1016/j.oraloncology.2005.08.001. View

Brown J, Ramalingam L, Zacharin M . Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?. Clin Endocrinol (Oxf). 2008; 68(6):863-7. DOI: 10.1111/j.1365-2265.2008.03189.x. View

Olutayo J, Agbaje J, Jacobs R, Verhaeghe V, Velde F, Vinckier F . Bisphosphonate-Related Osteonecrosis of the Jaw Bone: Radiological Pattern and the Potential Role of CBCT in Early Diagnosis. J Oral Maxillofac Res. 2014; 1(2):e3. PMC: 3886047. DOI: 10.5037/jomr.2010.1203. View

Chahine C, Cheung M, Head T, Schwartz S, Glorieux F, Rauch F . Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr. 2008; 153(5):719-20. DOI: 10.1016/j.jpeds.2008.05.003. View

Campisi G, Compilato D, Angelo I, Lo Muzio L, Colella G . Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: similarities with phossy jaw. Indian J Dent Res. 2013; 23(5):683-5. DOI: 10.4103/0970-9290.107408. View

Lin J . Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996; 18(2):75-85. DOI: 10.1016/8756-3282(95)00445-9. View

Schwartz S, Joseph C, Iera D, Vu D . Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc. 2008; 74(6):537-42. View

Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

10.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

11.

Pazianas M, Miller P, Blumentals W, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29(8):1548-58. DOI: 10.1016/j.clinthera.2007.08.008. View

12.

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

13.

Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tato L . Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr. 2006; 149(2):174-9. DOI: 10.1016/j.jpeds.2006.03.013. View

14.

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009; 35(3):119-30. DOI: 10.1111/j.1747-4477.2009.00213.x. View

15.

Mortensen M, Lawson W, Montazem A . Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope. 2007; 117(1):30-4. DOI: 10.1097/01.mlg.0000240885.64568.9e. View

16.

Glorieux F, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339(14):947-52. DOI: 10.1056/NEJM199810013391402. View

17.

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

18.

Papapoulos S . Bisphosphonates: how do they work?. Best Pract Res Clin Endocrinol Metab. 2008; 22(5):831-47. DOI: 10.1016/j.beem.2008.07.001. View

19.

Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L . Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005; 20(5):758-63. DOI: 10.1359/JBMR.041232. View

20.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007; 45(4):247-51. DOI: 10.1016/j.ypmed.2007.08.012. View